Cargando…

Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury

Background: Drug-induced liver injury (DILI) is a potentially serious adverse drug reaction. Due to the lack of definite etiology, specific clinical manifestations, and diagnostic methods, its prediction and diagnosis are challenging. Elderly individuals are deemed to be at high risk for DILI due to...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Yu-Ting, Wang, Jian-Fei, Niu, Xiao-Xia, Fu, Yi-Ming, Wang, Ke-Xin, Wang, Chun-Yan, Li, Qian-Qian, Wang, Jian-Jun, Zhao, Jun, Ji, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978525/
https://www.ncbi.nlm.nih.gov/pubmed/36874016
http://dx.doi.org/10.3389/fphar.2023.1071709
_version_ 1784899542504701952
author Xiong, Yu-Ting
Wang, Jian-Fei
Niu, Xiao-Xia
Fu, Yi-Ming
Wang, Ke-Xin
Wang, Chun-Yan
Li, Qian-Qian
Wang, Jian-Jun
Zhao, Jun
Ji, Dong
author_facet Xiong, Yu-Ting
Wang, Jian-Fei
Niu, Xiao-Xia
Fu, Yi-Ming
Wang, Ke-Xin
Wang, Chun-Yan
Li, Qian-Qian
Wang, Jian-Jun
Zhao, Jun
Ji, Dong
author_sort Xiong, Yu-Ting
collection PubMed
description Background: Drug-induced liver injury (DILI) is a potentially serious adverse drug reaction. Due to the lack of definite etiology, specific clinical manifestations, and diagnostic methods, its prediction and diagnosis are challenging. Elderly individuals are deemed to be at high risk for DILI due to abnormal pharmacokinetics, aging tissue repair function, comorbidities, and taking multiple drugs. This study aimed to identify the clinical characteristics and explore the risk factors associated with the severity of illness in elderly patients with DILI. Methods: In the present study, the clinical characteristics at the time of liver biopsy of consecutive patients with biopsy-proven DILI who presented at our hospital from June 2005 to September 2022 were evaluated. Hepatic inflammation and fibrosis were assessed according to the Scheuer scoring system. The presence of autoimmunity was considered if IgG level >1.1 × ULN (1826 mg/dL), or high titer (>1:80) of ANA, or SMA. Results: In total, 441 patients were enrolled, and the median age was 63.3 years (IQR, 61.0–66.0); 122 (27.7%), 195 (44.2%), or 124 (28.1%) were classified as having minor, moderate, or severe hepatic inflammation, respectively; and 188 (42.6%), 210 (47.6%) or 43 (9.8%) patients presented minor, significant fibrosis or cirrhosis, respectively. Female sex (73.5%) and the cholestatic pattern (47.6%) were dominant in elderly DILI patients. Autoimmunity existed in 201 patients (45.6%). Comorbidities were not directly associated with the severity of DILI. PLT (OR: 0.994, 95% CI: 0.991–0.997; p < 0.001), AST (OR: 1.001, 95% CI: 1.000–1.003, p = 0.012), TBIL (OR: 1.006, 95% CI: 1.003–1.010, p < 0.001), and autoimmunity (OR: 1.831, 95% CI: 1.258–2.672, p = 0.002) were associated with the degree of hepatic inflammation. Meanwhile, PLT (OR: 0.990, 95% CI: 0.986–0.993, p < 0.001), TBIL (OR: 1.004, 95% CI: 1.000–1.007, p = 0.028), age (OR: 1.123, 95% CI: 1.067–1.183, p < 0.001), and autoimmunity (OR: 1.760, 95% CI: 1.191–2.608, p = 0.005) were associated with the stage of hepatic fibrosis. Conclusion: This study revealed that the presence of autoimmunity represents a more serious illness state of DILI, deserving more intensive monitoring and progressive treatment.
format Online
Article
Text
id pubmed-9978525
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99785252023-03-03 Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury Xiong, Yu-Ting Wang, Jian-Fei Niu, Xiao-Xia Fu, Yi-Ming Wang, Ke-Xin Wang, Chun-Yan Li, Qian-Qian Wang, Jian-Jun Zhao, Jun Ji, Dong Front Pharmacol Pharmacology Background: Drug-induced liver injury (DILI) is a potentially serious adverse drug reaction. Due to the lack of definite etiology, specific clinical manifestations, and diagnostic methods, its prediction and diagnosis are challenging. Elderly individuals are deemed to be at high risk for DILI due to abnormal pharmacokinetics, aging tissue repair function, comorbidities, and taking multiple drugs. This study aimed to identify the clinical characteristics and explore the risk factors associated with the severity of illness in elderly patients with DILI. Methods: In the present study, the clinical characteristics at the time of liver biopsy of consecutive patients with biopsy-proven DILI who presented at our hospital from June 2005 to September 2022 were evaluated. Hepatic inflammation and fibrosis were assessed according to the Scheuer scoring system. The presence of autoimmunity was considered if IgG level >1.1 × ULN (1826 mg/dL), or high titer (>1:80) of ANA, or SMA. Results: In total, 441 patients were enrolled, and the median age was 63.3 years (IQR, 61.0–66.0); 122 (27.7%), 195 (44.2%), or 124 (28.1%) were classified as having minor, moderate, or severe hepatic inflammation, respectively; and 188 (42.6%), 210 (47.6%) or 43 (9.8%) patients presented minor, significant fibrosis or cirrhosis, respectively. Female sex (73.5%) and the cholestatic pattern (47.6%) were dominant in elderly DILI patients. Autoimmunity existed in 201 patients (45.6%). Comorbidities were not directly associated with the severity of DILI. PLT (OR: 0.994, 95% CI: 0.991–0.997; p < 0.001), AST (OR: 1.001, 95% CI: 1.000–1.003, p = 0.012), TBIL (OR: 1.006, 95% CI: 1.003–1.010, p < 0.001), and autoimmunity (OR: 1.831, 95% CI: 1.258–2.672, p = 0.002) were associated with the degree of hepatic inflammation. Meanwhile, PLT (OR: 0.990, 95% CI: 0.986–0.993, p < 0.001), TBIL (OR: 1.004, 95% CI: 1.000–1.007, p = 0.028), age (OR: 1.123, 95% CI: 1.067–1.183, p < 0.001), and autoimmunity (OR: 1.760, 95% CI: 1.191–2.608, p = 0.005) were associated with the stage of hepatic fibrosis. Conclusion: This study revealed that the presence of autoimmunity represents a more serious illness state of DILI, deserving more intensive monitoring and progressive treatment. Frontiers Media S.A. 2023-02-16 /pmc/articles/PMC9978525/ /pubmed/36874016 http://dx.doi.org/10.3389/fphar.2023.1071709 Text en Copyright © 2023 Xiong, Wang, Niu, Fu, Wang, Wang, Li, Wang, Zhao and Ji. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Xiong, Yu-Ting
Wang, Jian-Fei
Niu, Xiao-Xia
Fu, Yi-Ming
Wang, Ke-Xin
Wang, Chun-Yan
Li, Qian-Qian
Wang, Jian-Jun
Zhao, Jun
Ji, Dong
Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury
title Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury
title_full Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury
title_fullStr Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury
title_full_unstemmed Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury
title_short Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury
title_sort autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978525/
https://www.ncbi.nlm.nih.gov/pubmed/36874016
http://dx.doi.org/10.3389/fphar.2023.1071709
work_keys_str_mv AT xiongyuting autoimmunityassociateswithseverityofillnessinelderlypatientswithdruginducedliverinjury
AT wangjianfei autoimmunityassociateswithseverityofillnessinelderlypatientswithdruginducedliverinjury
AT niuxiaoxia autoimmunityassociateswithseverityofillnessinelderlypatientswithdruginducedliverinjury
AT fuyiming autoimmunityassociateswithseverityofillnessinelderlypatientswithdruginducedliverinjury
AT wangkexin autoimmunityassociateswithseverityofillnessinelderlypatientswithdruginducedliverinjury
AT wangchunyan autoimmunityassociateswithseverityofillnessinelderlypatientswithdruginducedliverinjury
AT liqianqian autoimmunityassociateswithseverityofillnessinelderlypatientswithdruginducedliverinjury
AT wangjianjun autoimmunityassociateswithseverityofillnessinelderlypatientswithdruginducedliverinjury
AT zhaojun autoimmunityassociateswithseverityofillnessinelderlypatientswithdruginducedliverinjury
AT jidong autoimmunityassociateswithseverityofillnessinelderlypatientswithdruginducedliverinjury